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Edited by Miguel De la RosaAbstract We investigate the hypothesis that heparin activates
antithrombin (AT) by relieving electrostatic strain within helix
D. Mutation of residues K125 and R129 to either Ala or Glu
abrogated heparin binding, but did not activate AT towards inhi-
bition of factors IXa or Xa. However, substitution of residues C-
terminal to helix D (R132 and K133) to Ala had minimal eﬀect
on heparin aﬃnity but resulted in appreciable activation. We
conclude that charge neutralization or reversal in the heparin
binding site does not drive the activating conformational change
of AT, and that the role of helix D elongation is to stabilize the
activated state.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Serpin; Protease; Allostery; Hemostasis;
Thrombosis1. Introduction
Antithrombin (AT) is the principal inhibitor of the coagula-
tion proteases. It circulates at a high concentration in a state
which is permissive of hemostasis (blood coagulation), and
its activation by heparin-like glycosaminoglycans is critical
for the cessation of clotting and the prevention of thrombosis.
Thus, regulation of AT activity is central to the ﬁne balance
between bleeding and thrombosis (for review see [1]). The acti-
vation of AT towards factors IXa and Xa (fIXa and fXa) is
signiﬁcantly allosteric in nature, as binding of AT to a speciﬁc
pentasaccharide sequence of heparin (H5) causes a two order
of magnitude increase in rates of inhibition (for review see
[2]). While biochemical [3–5] and structural studies [6,7] have
demonstrated the nature of the native and activated states,
how the conformational change is transduced from the heparin
binding site to the distant reactive center loop (RCL) remains
unresolved.
AT is a member of the serpin family of protease inhibitors
(for review see [8]), and as such, inhibits serine proteases by
incorporating its entire RCL into b-sheet A to trap the acyl-en-
zyme intermediate [9]. The structure of native AT diﬀers fromAbbreviations: AT, antithrombin; RCL, reactive center loop; fXa,
factor Xa; fIXa, factor IXa; H5, pentasaccharide; SI, stoichiometry of
inhibition
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doi:10.1016/j.febslet.2006.07.057the prototypical serpin a1-antitrypsin in that the N-terminal
portion of the RCL (the hinge region) is reversibly incorpo-
rated into b-sheet A (Fig. 1A, left). From kinetic studies it
has been estimated that at least 99% of circulating AT is in this
conformation, with less than 1% with a fully exposed RCL [5]
(Fig. 1A, right). AT binds to its cofactor H5 by a two step
mechanism summarized in Fig. 1A. Initial weak binding to
form an intermediate complex (Fig. 1A, middle) is followed
by a conformational change step which locks the pair in a
tight-binding complex (Fig. 1A, right). This induced-ﬁt mecha-
nism [10] causes conformational changes in the heparin bind-
ing site that somehow promote the expulsion of the hinge
region from b-sheet A. How this occurs is of great interest be-
cause it underlies the therapeutic anticoagulant eﬀect of hepa-
rin, and also because AT is the only heparin binding protein
known to utilize an induced-ﬁt mechanism to confer speciﬁcity
[11].
A hypothesis was put forward in 1994 to explain how H5
binding on helix D of AT was translated into hinge region
expulsion [12]. The principle of this ‘electrostatic hypothesis’
is that elongation of helix D towards its C-terminus would
engender electrostatic strain by lining up positively charged
residues K125, R129, R132 and K133 on the same face of
the helix. The strain in native AT prevents elongation of helix
D, but when H5 interacts the electrostatic repulsion is relieved,
thus promoting elongation. How helix D elongation might re-
sult in the expulsion of the hinge region of the RCL from b-
sheet A was not suggested, but the coupling of the two events
was supported by subsequent biochemical and structural stud-
ies [13–15]. Fig. 1B shows close-ups of the heparin binding re-
gion and b-sheet A which correspond to the structures shown
in A. Several conformational changes in the heparin binding
region are seen to occur upon interaction with H5, namely:
the one-turn extension of helix A towards the N-terminus,
the formation of a one-turn helix P just N-terminal to helix
D, and the one-turn C-terminal extension of helix D (Fig. 1B
right vs. left). However, helix A elongation and helix P forma-
tion are also observed in the intermediate state (Fig. 1B, mid-
dle), and also in the six-stranded latent form bound to H5
(Fig. 1C). Surprisingly, both structural changes were also ob-
served in the recent structure of native monomeric AT
(1T1F) (Fig. 1D). The only secondary structural change which
is uniquely observed in the hinge region-expelled state is thus
the C-terminal extension of helix D. These studies lend
credence to the electrostatic hypothesis which we set out to
investigate using a mutagenesis strategy aimed at both neutral-
izing the basic residues on and just C-terminal to helix D, and
by mimicking H5 binding by reversing the charges within theblished by Elsevier B.V. All rights reserved.
Fig. 1. Pentasaccharide binding induces several conformational
changes in AT. (A) AT is shown as a ribbon diagram in three
crystallographically determined conformational states: native (left),
intermediate (middle) and H5-activated (right, H5 as ball-and-stick).
The orientation was chosen to highlight the important structural
features of the RCL (yellow, with red ball-and-stick P1 residue), b-sheet
A (blue) and the heparin binding site (helix A in green and D in cyan).
In native and intermediate ATs the hinge region is partially inserted
into b-sheet A (circled). The secondary structural changes in the
heparin binding region are colored magenta. Helix A elongation and
helix P formation appear to be associated with the initial binding state,
and only helix D elongation is exclusively observed in the hinge region-
expelled (activated) state. (B) Close-ups of the heparin binding site, the
RCL and b-sheet A are shown under the structures to which they
correspond, and the residues mutated in this study are indicated. H5 is
shown as a transparent ball-and-stick. (C) The link between the state of
b-sheet A and the C-terminal portion of helix D is strengthened by the
observation that H5-bound latent AT has an elongated helix A and
helix P, but no elongation of helix D. (D) A similar result was found for
an unliganded monomeric structure of AT (1T1F).
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Fig. 2. Pentasaccharide binding and activation of AT variants. (A) H5
binding is detected by monitoring intrinsic ﬂuorescence enhancement
(DF is fractional ﬂuorescence change). Control AT (open circles) binds
with high aﬃnity and results in a 35% ﬂuorescence enhancement.
Similar results were found for the 132/133 Ala variant (open triangles),
but the 125/129 Ala variant (open inverted triangles) showed little
ﬂuorescence enhancement, even at high H5 concentrations. (B) H5
activation of fXa inhibition was normal for the control and 132/133
4710 J. Langdown et al. / FEBS Letters 580 (2006) 4709–4712helix. We found that mutation of K125 and R129 does not
activate AT, while mutation of the basic residues on the C-ter-
minal loop following helix D appreciably activated AT to-
wards both fIXa and fXa. The results demonstrate that
neutralization or reversal of the charges within the H5 binding
site does not drive the activating conformational change of
AT. However, the composition of the loop following helix D
is important, and its propensity to form an a-helix is integral
to the allosteric activation of AT.AT variants, while no acceleration was observed for the 125/129 Ala
variant, even with an excess of H5 (symbols as before). (C) However,
at very high H5 concentrations some acceleration of fXa inhibition was
seen for the 125/129 Ala (open inverted triangles) and the 125/129/132/
133 Ala (open diamonds) variants, reﬂecting a weak, but ﬁnite aﬃnity
for H5. The slopes are reported in Table 1 and were used to calculate
lower-limit Kds for the H5 interaction of 1 mM. The 125/129 Glu
variant, on the other hand, was insensitive to the presence of H5
indicating a total abolition of H5 binding.2. Materials and methods
2.1. Materials
Human a-thrombin and fIXa were obtained from Haematologic
Technologies (Essex Junction, VT), and human fXa was obtained from
Enzyme Research Laboratories (Swansea, UK). The pentasaccharide(fondaparinux, H5) was provided by Maurice Petitou (previously of
Sanoﬁ-Aventis), and the monoclonal antibody M27 [16] was the kind
gift of Johan Stenﬂo.
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AT variants K125E/R129E, K125A/R129A, R132A/K133A and
K125A/R129A/R132A/K133A were made in a baculovirus expression
system using the Bac-to-Bac system on the recombinant b-glycoform
background of S137A. The mutations were created by site-directed
mutagenesis of pFastBac1-AT plasmid using the Stratagene Quik-
Change site-directed mutagenesis kit with the appropriate primers
for the mutations. Invitrogen’s Bac-to-Bac procedures were followed
and transfection of Sf9 cells was performed using Fugene (Roche Diag-
nostics Ltd) following the manufacturers instructions. Three rounds of
viral ampliﬁcation were performed in Sf9 cells after which Hi-ﬁve cells
were infected (MOI of 0.2) and supernatant was harvested after 96 h.
AT puriﬁcation was achieved using a rabbit anti-human AT (Dako)
conjugated Sepharose column (for 125/129 variants), or heparin–Se-
pharose (for control S137A, and R132A/K133A). Further puriﬁcation
was achieved by Q-Sepharose chromatography. A monoclonal anti-
body speciﬁc for relaxed AT (latent, cleaved and polymers) [16] was
conjugated to NHS-activated Sepharose, and the column was used
to remove inactive AT. Puriﬁed AT variants were buﬀer exchanged
into 50 mM Tris, pH 7.4, concentrated to 1 mg/ml and stored in ali-
quots at 80 C. Thawed samples were fully active as assessed by
SDS–PAGE of reactions with thrombin, and stoichiometries of inhibi-
tion (SI) for all proteases (±H5) were indistinguishable from one for
each variant (SIs determined as previously [5]).2.3. Rates of inhibition and H5 binding
Second order rate constants of protease inhibition (±H5), and equi-
librium dissociation constants (Kd) for H5 binding were determined as
previously [5]. Kds for the AT variants containing the 125/129 Ala
mutations were calculated from the slope of kobs vs. high H5 concen-
tration (from Fig. 2C). An assumption that the same maximal rate
would be achieved for the variant as for the control (at full H5 occu-
pancy) allowed a calculation of the Kd from the following equation:
Kd = kpenta · [AT]0/slope  [AT]0 (kpenta is maximal second-order rate
constant and [AT]0 is total AT concentration).3. Results
3.1. Pentasaccharide binding
By following change in intrinsic ﬂuorescence with increasing
concentration of H5 we determined Kds for the control and
132/133 AT variants (Table 1, and Fig. 2A). It is known that
132 and 133 do not interact directly with H5, and accordingly
only a small 2.4-fold decrease in aﬃnity was observed. For the
other variants, involving mutation of residues 125 and 129, noTable 1
Pentasaccharide binding and protease inhibition by AT variants
Antithrombin Penta bindinga Second-order rate con
Kd (nM) Penta Thro
Control 2.5 ± 0.3  9.8 ±
(1) + 1.4 ±
R132A/K133A 6.1 ± 0.1  8.8 ±
(2.4) + 1.4 ±
K125A/R129A P 1000000*  7.9 ±
(P 400000) + NC
Quad Ala P 1000000  7.6 ±
(P 400000) + NC
K125E/K129E UD  8.0 ±
– + NC
aValue in parentheses corresponds to magnitude of reduction in H5 aﬃn
ﬂuorescence or activity. NC means no change and ND is for not determine
Fig. 2C, and the Kd values with an asterisk are calculated from the slopes abinding was detected by the ﬂuorescence method even at high
H5 concentrations (Fig. 2A).
3.2. Rates of protease inhibition
Mutations in AT often aﬀect the partitioning between the
substrate and inhibitory pathways, reﬂected by an increase in
the apparent SI. For the control and all helix D variants, how-
ever, we obtained SIs indistinguishable from one (±H5, data
not shown). Second-order rate constants of inhibition of
thrombin, fXa and fIXa (±H5) are reported in Table 1. Rates
of thrombin inhibition were normal for all AT variants. The
rates of fXa and fIXa inhibition are highly sensitive to the con-
formation of AT, with H5 binding resulting in a 126-fold and a
233-fold increase kapp for control AT. The basal rates (no H5)
of fXa and fIXa inhibition thus reﬂect the activating eﬀects of
the helix D mutations. We found that either neutralization or
reversal of the charges within the H5 binding region of helix D
(125/129) did not have any eﬀect on rates of inhibition, but
that neutralization of 132/133 resulted in a signiﬁcant increase
in rates of fXa (5.7-fold) and fIXa (7.9-fold) inhibition. The
quadruple Ala variant was slightly activated towards fXa
and fIXa (1.8 and 2.8-fold respectively), but less so than the
132/133 variant on its own.
Pentasaccharide activation for the 132/133 variant was nor-
mal for all three proteases, but could not be determined for the
125/129 variants due to the apparent loss of binding (Fig. 2B).
However, very high concentrations H5 did increase the ob-
served rate of inhibition of fXa for the two 125/129 Ala vari-
ants (slopes reported in Table 1), but no eﬀect was seen
under these conditions for the 125/129 Glu variant (Fig. 2C).
These results suggest a ﬁnite H5 aﬃnity of the 125/129 Ala
variants. Assuming that upon saturation of H5 binding the
rate of fXa inhibition would be equivalent for the 125/129
Ala variants and the control, a lower-limit Kd of 1 mM can
be estimated for the 125/129 Ala variants.4. Discussion
This study was undertaken to test the long-standing elec-
trostatic hypothesis of AT activation [12]. It was proposedstants of protease inhibition (M1 s1)
mbin Factor Xa Factor IXa
0.14 · 103 6.1 ± 0.07 · 103 1.2 ± 0.09 · 102
0.1 · 104 7.7 ± 0.002 · 105 2.8 ± 0.29 · 104
0.10 · 103 3.5 ± 0.11 · 104 9.5 ± 1.3 · 102
0.06 · 104 7.5 ± 0.06 · 105 3.1 ± 0.21 · 104
0.02 · 103 5.0 ± 0.11 · 103 1.1 ± 0.08 · 102
[1.5 ± 0.03 · 102] ND
0.40 · 103 1.1 ± 0.04 · 104 3.4 ± 0.13 · 102
[1.7 ± 0.01 · 102] ND
0.30 · 103 5.5 ± 0.03 · 103 1.5 ± 0.17 · 102
[0] ND
ity relative to control. UD indicates undetectable binding by either
d. Values in square brackets are the slopes from the graph shown in
ccording to the equation in Section 2.
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(i.e. K125 and R129) upon interaction with H5 would
promote helix D elongation (including R132 and K133),
and that helix D elongation provides the driving force for
the AT conformational change which results in hinge region
expulsion from b-sheet A (Fig. 1A and B). Subsequent struc-
tural and biochemical studies have demonstrated that helix D
elongation is associated with, and energetically coupled to H5
binding, but the role of charge neutralization in propagating
helix D elongation has not been investigated. We thus created
variants which neutralized the charges within the H5 binding
site on helix D (K125A/R129A) and in the following loop re-
gion (R132A/K133A). We also created a variant designed to
mimic the eﬀect of H5 binding by reversing the charges in the
heparin binding site (K125E/R129E). These mutations were
not predicted to alter the core structure of AT because the
residues are found in diﬀerent conformations in the many
structures of unliganded AT, and in some cases their side
chains were missing from electron density, indicating a high
degree of ﬂexibility. This was indeed borne out by the obser-
vation that the variants were fully active inhibitors of all
three proteases tested, and thus any observed eﬀect of the
mutations derived from either local alterations in structure
or electrostatic potential. Our results show that neutralization
or reversal of the positive charges within the H5 binding site
does not mimic the eﬀect of H5 binding. Such an eﬀect would
have resulted in a signiﬁcant increase in the rates of fIXa and
Xa inhibition, and none was not observed. These results are
consistent with data obtained from single mutations in the
heparin binding region [17,18], and argue strongly against
the electrostatic hypothesis.
However, neutralization of residues on the extended helix D
(R132/K133) did marginally activate AT towards fIXa and
fXa. This is likely to reﬂect a change in the equilibrium be-
tween the native hinge region-inserted form and the activated
hinge region-expelled form. It is well established that the acti-
vating conformational change is the release hinge region from
b-sheet A [5], thus, any observed increase in basal rate of fIXa
or fXa inhibition is caused by an increase in population of the
hinge region-expelled state. Factor IXa is particularly sensitive
to the expulsion of the hinge region, as prevention of hinge re-
gion extension totally abrogates fIXa inhibition. Thus, the low
basal rate of fIXa inhibition reﬂects the small fraction of AT in
an activated state (assuming a rapid equilibrium). Based on
rates of fIXa inhibition we estimate that about 0.4% of wild-
type AT is in the activated state and neutralization of 132/
133 results in about 3% in the activated state. How these muta-
tions alter the equilibrium is unclear, however, it is unlikely to
be the result of charge neutralization as several other muta-
tions in this region have similar eﬀects. Failure to glycosylate
at Asn135 (plasma b-glycoform) increases heparin aﬃnity
and rates of protease inhibition, and recombinant b-forms cre-
ated by mutating either Asn135 or Ser137 lead to an even
greater increase [19–21]. These eﬀects might be explained by
an increase in the helical propensity of the C-terminal helix
D loop, but the small increase in fraction in the activated state
observed for the 132/133 Ala variant suggests that helix D
elongation is not the conformational event which drives hinge
region expulsion. Rather, helix D elongation is likely to occur
after hinge region expulsion, perhaps, as previously suggested
[15], to stabilize the activated state.Acknowledgements: Funding is provided by the NIH (R01 HL68629),
the MRC (UK) and the Tesny-Perry Trust.References
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